{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:26:30Z","timestamp":1792700790248,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,10,3]],"date-time":"2009-10-03T00:00:00Z","timestamp":1254528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s10549-009-0570-3","type":"journal-article","created":{"date-parts":[[2009,10,2]],"date-time":"2009-10-02T06:22:21Z","timestamp":1254464541000},"page":"325-336","source":"Crossref","is-referenced-by-count":33,"title":["Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-\u03b1 in a model of metastatic breast cancer"],"prefix":"10.1007","volume":"122","author":[{"given":"Michael S.","family":"Sabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent A.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,3]]},"reference":[{"issue":"2","key":"570_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1245\/ASO.2004.03.022","volume":"11","author":"MS Sabel","year":"2004","unstructured":"Sabel MS, Skitzki J, Stoolman L et al (2004) Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol 11(2):147\u2013156","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"570_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CJI.0b013e318156e6a7","volume":"30","author":"MS Sabel","year":"2007","unstructured":"Sabel MS, Arora A, Su G et al (2007) Generation of a tumor-specific systemic repsonse after intratumoral injection of IL-12 and IL-18 loaded polylactic acid microspheres. J Immunother 30(8):808\u2013815","journal-title":"J Immunother"},{"key":"570_CR3","doi-asserted-by":"crossref","unstructured":"Pulaski BA, Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumor model. Curr Protoc Immunol. Chapter 20(Unit 20.2)","DOI":"10.1002\/0471142735.im2002s39"},{"key":"570_CR4","doi-asserted-by":"crossref","unstructured":"Schultz J, Heinzerling L, Pavlovic J, Moelling K (2000) Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. Cancer Gene Ther 7(12):1557\u20131565","DOI":"10.1038\/sj.cgt.7700273"},{"key":"570_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/386410a0","volume":"386","author":"E Mathiowitz","year":"1997","unstructured":"Mathiowitz E, Jacob JS, Jong YS et al (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386:410\u2013414","journal-title":"Nature"},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","volume":"13","author":"MP Colombo","year":"2002","unstructured":"Colombo MP, Trinchieri G (2002) Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155\u2013168","journal-title":"Cytokine Growth Factor Rev"},{"key":"570_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133\u2013146","journal-title":"Nat Rev Immunol"},{"key":"570_CR8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-002-0356-5","volume":"52","author":"JEA Portielje","year":"2003","unstructured":"Portielje JEA, Gratama JW, van Ojik HH et al (2003) IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52:133\u2013144","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"570_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0952-7915(98)80226-4","volume":"10","author":"FJ Lejeune","year":"1998","unstructured":"Lejeune FJ, Ruegg C, Lienard D (1998) Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10(5):573\u2013580","journal-title":"Curr Opin Immunol"},{"key":"570_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R Horssen van","year":"2006","unstructured":"van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-alpha in cancer treatment: molecular insights, antitumor effects and clinical utility. Oncologist 11:397\u2013408","journal-title":"Oncologist"},{"key":"570_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00262-005-0081-y","volume":"55","author":"K Tamada","year":"2006","unstructured":"Tamada K, Chen L (2006) Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 55:355\u2013362","journal-title":"Cancer Immunol Immunother"},{"key":"570_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2004.11.001","volume":"16","author":"S Mocellin","year":"2005","unstructured":"Mocellin S, Rossi CR, Pilati P, Nitti D (2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35\u201353","journal-title":"Cytokine Growth Factor Rev"},{"key":"570_CR13","first-page":"1678","volume":"6","author":"JA Gollob","year":"2000","unstructured":"Gollob JA, Mier JW, Korina V et al (2000) Phase I trial of twice-weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6:1678\u20131692","journal-title":"Clin Cancer Res"},{"key":"570_CR14","first-page":"75","volume":"4","author":"E Bajetta","year":"1998","unstructured":"Bajetta E, Del Vecchio M, Mortarini R et al (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4:75\u201385","journal-title":"Clin Cancer Res"},{"key":"570_CR15","first-page":"409","volume":"3","author":"MB Atkins","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409\u2013417","journal-title":"Clin Cancer Res"},{"key":"570_CR16","first-page":"9","volume":"5","author":"MJ Robertson","year":"1999","unstructured":"Robertson MJ, Cameron C, Atkins MB et al (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5:9\u201316","journal-title":"Clin Cancer Res"},{"key":"570_CR17","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard JP, Sherman ML, Fisher GL et al (1997) Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-gamma production. Blood 90:2541\u20132548","journal-title":"Blood"},{"key":"570_CR18","unstructured":"Tahara H, Zitvogel L, Storkus WJ et al (1997) Antitumor effects in patients with melanoma, head and neck and breast cancer in a phase I\/II clinical trial of IL-12. Proc Am Soc Clin Oncol 16:439a"},{"issue":"5","key":"570_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1200\/JCO.2005.00.463","volume":"23","author":"G Mazzolini","year":"2005","unstructured":"Mazzolini G, Alfaro C, Sangro B et al (2005) Intratumoral injection of dendritic cells engineered to secrete Interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23(5):999\u20131010","journal-title":"J Clin Oncol"},{"key":"570_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.gt.3300731","volume":"5","author":"CL Addison","year":"1998","unstructured":"Addison CL, Bramson JL, Hitt MM et al (1998) Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 5:1400\u20131409","journal-title":"Gene Ther"},{"key":"570_CR21","doi-asserted-by":"crossref","unstructured":"Gambotto A, Tuting T, McVey DL et al (1999) Induction of antitumor immunity by direct intratumoral injection of recombinant adenovirus vector expressing Interleukin-12. Cancer Gene Ther 6(1):45\u201353","DOI":"10.1038\/sj.cgt.7700013"},{"key":"570_CR22","doi-asserted-by":"crossref","unstructured":"Nasu Y, Bangma CH, Hull GW et al (1999) Adenovirus-mediated interleukin-12 gene therapy for prostate cancer suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6:338\u2013349","DOI":"10.1038\/sj.gt.3300834"},{"key":"570_CR23","doi-asserted-by":"crossref","unstructured":"Kianmanesh A, Hackett NR, Lee JM et al (2001) Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Human Gene Ther 12(17):2035\u20132049","DOI":"10.1089\/10430340152677395"},{"key":"570_CR24","doi-asserted-by":"crossref","unstructured":"Liu Y, Ehtesham M, Samoto K et al (2002) In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9(1):9\u201315","DOI":"10.1038\/sj.cgt.7700399"},{"issue":"12","key":"570_CR25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.cgt.7700538","volume":"9","author":"MJ Mastrangelo","year":"2002","unstructured":"Mastrangelo MJ, Lattime EC (2002) Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther 9(12):1013\u20131021","journal-title":"Cancer Gene Ther"},{"issue":"20","key":"570_CR26","first-page":"6956","volume":"63","author":"AS Yang","year":"2003","unstructured":"Yang AS, Monken CE, Lattime EC (2003) Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte\u2013macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res 63(20):6956\u20136961","journal-title":"Cancer Res"},{"issue":"3","key":"570_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1034\/j.1600-0625.2001.110306.x","volume":"11","author":"L Heinzerling","year":"2002","unstructured":"Heinzerling L, Dummer R, Pavlovic J et al (2002) Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol 11(3):232\u2013240","journal-title":"Exp Dermatol"},{"key":"570_CR28","doi-asserted-by":"crossref","unstructured":"Tanigawa K, Yu H, Sun R et al (2000) Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother 48:635\u2013643","DOI":"10.1007\/s002620050012"},{"issue":"3","key":"570_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.cgt.7700287","volume":"8","author":"E Hanna","year":"2001","unstructured":"Hanna E, Zhang X, Woodlis J et al (2001) Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther 8(3):151\u2013157","journal-title":"Cancer Gene Ther"},{"key":"570_CR30","doi-asserted-by":"crossref","unstructured":"Heinzerling LM, Feige K, Rieder S et al (2001) Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med 78(12):692\u2013702","DOI":"10.1007\/s001090000165"},{"issue":"1","key":"570_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1365-2249.2000.01112.x","volume":"119","author":"N Haicheur","year":"2000","unstructured":"Haicheur N, Escudier B, Dorval T et al (2000) Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 119(1):28\u201337","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"570_CR32","first-page":"76","volume":"9","author":"JE Portielje","year":"2003","unstructured":"Portielje JE, Lamers CH, Kruit WH et al (2003) Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, TNF-alpha, IL-6 and IL-8 responses. Clin Cancer Res 9(1):76\u201383","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-009-0570-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-009-0570-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T19:09:23Z","timestamp":1590174563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-009-0570-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s10549-009-0570-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,3]]}}}